Demographic and clinical characteristics of malignant multiple sclerosis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Multiple sclerosis (MS) that causes patients to require assistance for ambulation (Expanded Disability Status Scale [EDSS] ≥6) within 5 years from symptom onset is generally termed malignant. Malignant status can be transient (TM) or sustained until year 5 (SM). We studied the incidence, predictors, and demographic and clinical characteristics of malignant MS.
Methods: Patients with symptom onset in 2002–2005 and 5-year follow-up were selected from the Partners Multiple Sclerosis Center database. Patients with TM were further grouped into TM and SM. The mechanism of reaching EDSS 6 (relapse- vs progression-related) was determined.
Results: A total of 487 patients were included (17 TM, 42 SM). The incidence proportion of ever malignant (EM = SM+TM) was estimated as 12.11% and SM as 8.62%. Patients with older age at onset, male gender, and positive smoking history were more likely to become SM. Compared to nonmalignant patients, the proportion of progressive-onset MS in the SM group was significantly higher, but not different in TM. Within relapsing-onset patients, most of TM, and a smaller proportion of the SM group had a relapse-related as opposed to progression-related mechanism. The final model predictors for EM vs nonmalignant were older age at onset, motor symptoms at onset, and progressive disease onset. Within the malignant patients, predictors of TM vs SM were younger age and brainstem symptoms at onset.
Conclusions: Over 10% of patients with MS experience a malignant course as defined above. Some demographic and clinical factors are found to predict a malignant outcome. MS in patients who reach a high EDSS based on disease progression is more likely to remain malignant.
Footnotes
Study funding: Supported by the National Multiple Sclerosis Society (TC-RG-4256A4/2) and EMD Serono, Inc. (HLW-Independent Investigator Award-CLIMB).
-
Supplemental data at www.neurology.org
-
- CLIMB
- Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital
- EDSS
- Expanded Disability Status Scale
- EM
- ever malignant
- FS
- functional systems
- MS
- multiple sclerosis
- NM
- nonmalignant
- SM
- sustained malignant status
- TM
- transient malignant status.
- Received December 10, 2010.
- Accepted February 18, 2011.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Age and disability accumulation in multiple sclerosisA. Scalfari, A. Neuhaus, M. Daumer et al.Neurology, September 14, 2011 -
Article
Relapses and disability accumulation in progressive multiple sclerosisM. Mateo Paz Soldán, Martina Novotna, Nuhad Abou Zeid et al.Neurology, November 14, 2014 -
Article
Poor early relapse recovery affects onset of progressive disease course in multiple sclerosisMartina Novotna, M. Mateo Paz Soldán, Nuhad Abou Zeid et al.Neurology, July 24, 2015 -
Articles
The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosisJ. H. Noseworthy, P. O'Brien, B. J. Erickson et al.Neurology, November 01, 1998